Skip to main content

Table 1 Patient characteristics at baseline

From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

  All
(n = 409)
irAEs ( +)
(n = 138)
irAEs (-)
(n = 271)
P value
Age, years 69 (60–74) 70 (60–74) 69 (60–74) 0.32
Gender (male) 288 (70.4) 94 (68.7) 194 (71.6) 0.49
BMI, kg/m2 20.9 (18.1–23.4) 21.7 (18.5–24.0) 20.5 (17.9–23.2) 0.04
Pulse rate, bpm 82 (73–93) 81 (71–91) 84 (74–94) 0.12
Systolic blood pressure, mmHg 120 (107–134) 123 (111–134) 118 (106–133) 0.14
Diastolic blood pressure, mmHg 72 (64–81) 72 (64–81) 72 (64–82) 0.70
Cancer type
 Non-small cell lung cancer 170 (41.6) 59 (42.8) 111 (41.0) 0.75
 Malignant melanoma 82 (20.0) 42 (30.4) 40 (14.8)  < 0.01
 Renal cancer 43 (10.5) 20 (14.5) 23 (8.5) 0.09
 Stomach cancer 35 (8.6) 4 (2.9) 31 (11.4) 0.003
 Pharyngeal cancer 21 (5.1) 3 (2.2) 18 (6.6) 0.059
 Paranasal cancer 7 (1.7) 2 (1.4) 5 (1.8) 1
 Tongue cancer 7 (1.7) 1 (0.7) 6 (2.2) 0.43
 Bladder cancer 6 (1.5) 1 (0.7) 5 (1.8) 0.67
 Mesothelioma 5 (1.2) 0 (0) 5 (1.8) 0.17
 Other cancer 33 (8.1) 6 (4.3) 27 (10.0) 0.056
Comorbidity
 Hypertension 162 (39.6) 60 (43.5) 102 (37.6) 0.29
 Diabetes mellitus 74 (18.1) 27 (19.6) 47 (17.3) 0.59
 Dyslipidemia 72 (17.6) 31 (22.5) 41 (15.1) 0.075
Cardiovascular history
 Coronary artery disease 34 (8.3) 15 (10.9) 19 (7.0) 0.19
 Arrythmia 24 (5.9) 11 (8.0) 13 (4.8) 0.27
 Heart failure 5 (1.2) 2 (1.4) 3 (1.1) 1
 Venous thrombosis 8 (2.0) 0 (0) 8 (3.0) 0.06
 Pericardial disease 3 (0.7) 0 (0) 3 (1.1) 0.55
Medication
 ACE-I/ARB 81 (19.8) 35 (25.4) 47 (17.3) 0.067
 Beta-blockers 34 (8.3) 15 (10.9) 19 (7.0) 0.26
 Ca-channel blockers 118 (28.9) 43 (31.2) 75 (27.7) 0.49
 Statins 57 (13.9) 23 (16.7) 34 (12.5) 0.29
 Diuretics 28 (6.8) 6 (4.3) 27 (10.0) 0.21
Laboratory measurements
 TP, mg/dL 6.8 (6.3–7.1) 6.8 (6.5–7.0) 6.7 (6.3–7.2) 0.37
 Alb, mg/dL 3.7 (3.3–4.0) 3.8 (3.4–4.1) 3.7 (3.2–4.0) 0.01
 Cre, mg/dL 0.79 (0.65–1.00) 0.78 (0.64–1.00) 0.79 (0.65–1.00) 0.91
 CRP, md/dL 0.42 (0.10—1.80) 0.23 (0.07—1.12) 0.56 (0.13 – 2.28) 0.004
 WBC, /103 6.0 (4.9—7.7) 5.9 (4.9 – 7.3) 6.0 (4.9—7.8) 0.44
 Hb, mg/dL 11.8 (10.4–13.0) 12.0 (10.9–13.2) 11.7 (10.3–12.9) 0.033
Chest radiography
 CTR, % 46.5 (42.6–50.1) 46.8 (42.8–50.2) 46.3 (42.5–50.1) 0.56
  1. irAEs immune-Related Adverse Events, BMI body mass index, ACE-I angiotensin-converting-enzyme inhibitor, ARB Angiotensin II Receptor Blocker, TP total protein, Alb albumin, Cre creatinine, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, CTR cardiothoracic ratio